Funding The authors gratefully acknowledge use of the services and facilities of the Ko University Research Center for Translational Medicine (KUTTAM), funded by the Republic of Turkey Ministry of Development
Avoiding Smoking and Excess Alcohol Consumption A number of environmental factors can affect eye health
Behavioral and Metabolic Optimization Strategies Hitting a plateau does not mean tirzepatide has stopped working
Effects of Semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial
Major cardiovascular outcome trials include: LEADER trial (liraglutide): Demonstrated a significant reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and high cardiovascular risk SUSTAIN-6 (semaglutide): Showed reduced cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke REWIND (dulaglutide): Confirmed cardiovascular benefits across a broad patient population SELECT trial (semaglutide): Showed reduced MACE in people with obesity without diabetes, though this evidence is not yet fully incorporated into UK labelling [17] These trials consistently found that the modest heart rate increases observed did not translate into adverse cardiovascular outcomes

Gastro-intestinal symptoms score was assessed based on the score of Adam and collaborators 16 as follows: Parents were asked to indicate whether their children had experienced specific GI symptoms nausea, vomiting, bloating, abdominal cramps, early satiety, eructation or heartburn, loss of appetite, retrosternal discomfort and epigastric pain or abdominal pain over the past month